Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.24
ZTS's Cash to Debt is ranked higher than
53% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. ZTS: 0.24 )
ZTS' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.24

Equity to Asset 0.20
ZTS's Equity to Asset is ranked lower than
51% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. ZTS: 0.20 )
ZTS' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.65
Current: 0.2

0.14
0.65
Interest Coverage 8.07
ZTS's Interest Coverage is ranked higher than
56% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. ZTS: 8.07 )
ZTS' s 10-Year Interest Coverage Range
Min: 2.3   Max: 13.28
Current: 8.07

2.3
13.28
F-Score: 8
Z-Score: 4.46
M-Score: -2.62
WACC vs ROIC
7.42%
16.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 19.73
ZTS's Operating margin (%) is ranked higher than
90% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. ZTS: 19.73 )
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53   Max: 19.73
Current: 19.73

-4.53
19.73
Net-margin (%) 12.18
ZTS's Net-margin (%) is ranked higher than
85% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. ZTS: 12.18 )
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62   Max: 12.18
Current: 12.18

-3.62
12.18
ROE (%) 48.98
ZTS's ROE (%) is ranked higher than
99% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. ZTS: 48.98 )
ZTS' s 10-Year ROE (%) Range
Min: 11.26   Max: 51.8
Current: 48.98

11.26
51.8
ROA (%) 8.94
ZTS's ROA (%) is ranked higher than
89% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. ZTS: 8.94 )
ZTS' s 10-Year ROA (%) Range
Min: 7.28   Max: 8.86
Current: 8.94

7.28
8.86
ROC (Joel Greenblatt) (%) 32.66
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. ZTS: 32.66 )
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88   Max: 36.32
Current: 32.66

25.88
36.32
Revenue Growth (3Y)(%) 4.00
ZTS's Revenue Growth (3Y)(%) is ranked higher than
71% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. ZTS: 4.00 )
ZTS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 8.4
Current: 4

0
8.4
EBITDA Growth (3Y)(%) 21.40
ZTS's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. ZTS: 21.40 )
ZTS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 36.2
Current: 21.4

0
36.2
EPS Growth (3Y)(%) 33.30
ZTS's EPS Growth (3Y)(%) is ranked higher than
93% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. ZTS: 33.30 )
ZTS' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 66.2
Current: 33.3

0
66.2
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ZTS Guru Trades in Q2 2014

Pioneer Investments 2,254,815 sh (+17.86%)
George Soros 4,386,635 sh (+4.32%)
Vanguard Health Care Fund 10,798,417 sh (+3.61%)
Ruane Cunniff 173,562 sh (+0.01%)
Robert Olstein 178,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
RS Investment Management 2,548,819 sh (-5.16%)
John Keeley 74,504 sh (-5.82%)
Mario Gabelli 242,980 sh (-6.74%)
Joel Greenblatt 33,034 sh (-22.04%)
Jean-Marie Eveillard 2,177,060 sh (-42.15%)
» More
Q3 2014

ZTS Guru Trades in Q3 2014

Bill Ackman 5,536,862 sh (New)
John Keeley 79,504 sh (+6.71%)
Robert Olstein 178,000 sh (unchged)
Vanguard Health Care Fund 10,798,417 sh (unchged)
Pioneer Investments 2,203,980 sh (unchged)
Joel Greenblatt Sold Out
Jean-Marie Eveillard 2,174,162 sh (-0.13%)
Ruane Cunniff 173,322 sh (-0.14%)
RS Investment Management 2,491,074 sh (-2.27%)
George Soros 4,031,735 sh (-8.09%)
Mario Gabelli 217,980 sh (-10.29%)
» More
Q4 2014

ZTS Guru Trades in Q4 2014

Jim Simons 650,500 sh (New)
Steven Cohen 1,718,300 sh (New)
Bill Ackman 41,569,646 sh (+650.78%)
Mario Gabelli 626,893 sh (+187.59%)
George Soros 4,106,735 sh (+1.86%)
Ruane Cunniff 173,423 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Pioneer Investments 2,202,773 sh (-0.05%)
Vanguard Health Care Fund 9,178,657 sh (-15.00%)
Robert Olstein 141,000 sh (-20.79%)
John Keeley 62,164 sh (-21.81%)
Jean-Marie Eveillard 820,467 sh (-62.26%)
RS Investment Management 212,262 sh (-91.48%)
» More
2015

ZTS Guru Trades in 2015

Bill Ackman 41,823,145 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 40.00
ZTS's P/E(ttm) is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. ZTS: 40.00 )
ZTS' s 10-Year P/E(ttm) Range
Min: 27.31   Max: 42.59
Current: 40

27.31
42.59
Forward P/E 24.63
ZTS's Forward P/E is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. ZTS: 24.63 )
N/A
PE(NRI) 40.80
ZTS's PE(NRI) is ranked higher than
80% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. ZTS: 40.80 )
ZTS' s 10-Year PE(NRI) Range
Min: 27.31   Max: 42.59
Current: 40.8

27.31
42.59
P/B 17.80
ZTS's P/B is ranked lower than
55% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. ZTS: 17.80 )
ZTS' s 10-Year P/B Range
Min: 12.65   Max: 24.37
Current: 17.8

12.65
24.37
P/S 4.85
ZTS's P/S is ranked higher than
61% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. ZTS: 4.85 )
ZTS' s 10-Year P/S Range
Min: 3.11   Max: 5
Current: 4.85

3.11
5
PFCF 52.50
ZTS's PFCF is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. ZTS: 52.50 )
ZTS' s 10-Year PFCF Range
Min: 25.57   Max: 90.29
Current: 52.5

25.57
90.29
POCF 38.18
ZTS's POCF is ranked higher than
77% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. ZTS: 38.18 )
ZTS' s 10-Year POCF Range
Min: 21.59   Max: 41.99
Current: 38.18

21.59
41.99
EV-to-EBIT 28.07
ZTS's EV-to-EBIT is ranked higher than
81% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. ZTS: 28.07 )
ZTS' s 10-Year EV-to-EBIT Range
Min: 20.9   Max: 28.2
Current: 28.07

20.9
28.2
Current Ratio 3.19
ZTS's Current Ratio is ranked higher than
78% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. ZTS: 3.19 )
ZTS' s 10-Year Current Ratio Range
Min: 2.37   Max: 3.19
Current: 3.19

2.37
3.19
Quick Ratio 2.00
ZTS's Quick Ratio is ranked higher than
75% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ZTS: 2.00 )
ZTS' s 10-Year Quick Ratio Range
Min: 1.35   Max: 2
Current: 2

1.35
2
Days Inventory 281.54
ZTS's Days Inventory is ranked higher than
58% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. ZTS: 281.54 )
ZTS' s 10-Year Days Inventory Range
Min: 117.43   Max: 288.46
Current: 281.54

117.43
288.46
Days Sales Outstanding 74.75
ZTS's Days Sales Outstanding is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. ZTS: 74.75 )
ZTS' s 10-Year Days Sales Outstanding Range
Min: 74.75   Max: 91.07
Current: 74.75

74.75
91.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.65
ZTS's Dividend Yield is ranked lower than
76% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.46 vs. ZTS: 0.65 )
ZTS' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.94
Current: 0.65

0.21
0.94
Dividend Payout 0.25
ZTS's Dividend Payout is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.92 vs. ZTS: 0.25 )
ZTS' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.25
Current: 0.25

0.19
0.25
Yield on cost (5-Year) 0.60
ZTS's Yield on cost (5-Year) is ranked lower than
78% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ZTS: 0.60 )
ZTS' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.94
Current: 0.6

0.21
0.94
Share Buyback Rate -0.10
ZTS's Share Buyback Rate is ranked higher than
87% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.60 vs. ZTS: -0.10 )
ZTS' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.1
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.40
ZTS's Price/Median PS Value is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. ZTS: 1.40 )
ZTS' s 10-Year Price/Median PS Value Range
Min: 1   Max: 1.26
Current: 1.4

1
1.26
Earnings Yield (Greenblatt) 3.60
ZTS's Earnings Yield (Greenblatt) is ranked higher than
79% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ZTS: 3.60 )
ZTS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 4.8
Current: 3.6

3.5
4.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:ZOE.Germany,
Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight core species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses; and five product categories: anti-infectives - products that prevent, kill or slow the growth of bacteria, fungi or protozoa; vaccines - biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response; parasiticides - products that prevent or eliminate external and internal parasites such as fleas, ticks and worms; medicated feed additives; and other pharmaceutical products - pain and sedation, oncology, antiemetic, allergy and dermatology; and reproductive products. The Company organizes and operates its business in four segments: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It primarily sells its companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc. (formerly known as Intervet/Schering-Plough); Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world.
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Bill Ackman is keeping on buying Zoetis Feb 24 2015 
Activist Investor Bill Ackman's Newest Additions to His Portfolio Feb 18 2015 
Feeling Good With This Med Company Jan 20 2015 
2015 - First Half Jan 01 2015 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis Nov 12 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Guru Stocks at 52-Week Lows: HMC, NMR, SDRL, ZTS, BBBY Apr 21 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows Apr 10 2014 

More From Other Websites
The young & the restless: 6 who are hot Mar 27 2015
With New Valeant Pharmaceuticals Intl Inc (VRX) Stake, Bill Ackman Maintains Large Exposure to... Mar 26 2015
Zoetis Call-Buyers at Work in Shares of the Animal Health Company Mar 26 2015
U.S. developing bird flu vaccine, no distribution plans yet Mar 23 2015
Herding cattle? There's an app for that Mar 19 2015
Panel of Experts Calls for Closer Collaboration Between Human and Animal Health Mar 16 2015
Wednesday's Swing Set Ups Mar 11 2015
Alibaba Group Holding (BABA), Teva Pharmaceutical Industries (TEVA): George Soros and Billionaires... Mar 10 2015
ZOETIS INC. Financials Mar 06 2015
ZOETIS INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 04 2015
Zoetis to Participate in the Jefferies 2015 Animal Health Summit Mar 02 2015
Zoetis Declares Second Quarter 2015 Dividend Feb 27 2015
ZOETIS INC. Files SEC form 8-K, Regulation FD Disclosure Feb 27 2015
Zoetis Declares Second Quarter 2015 Dividend Feb 27 2015
Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Feb 27 2015
Trade Ideas Feb 25 2015
Billionaire Bill Ackman’s Top Picks: Allergan Inc. (AGN), Air Products & Chemicals Inc. (APD),... Feb 19 2015
13F Watch: In Defense of Active Share Feb 19 2015
Zoetis to Participate in the Barclays Global Healthcare Conference Feb 18 2015
Zoetis to Participate in the Barclays Global Healthcare Conference Feb 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK